BriaCell Therapeutics Corp(BCTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:03 PM ET (Korea 10/31 05:03)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -9.33 | Insider Own | 0.15% | Shs Outstand | 8.7M | Perf Week | -11.5% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -26.03% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 14.08% | Short Float | - | Perf Quarter | -9.52% |
| Income | -0.03B | P/S | - | EPS this Y | - | Inst Trans | 1.49% | Short Ratio | 3 | Perf Half Y | -27.27% |
| Sales | 0.00B | P/B | 1.61 | EPS next 5Y | - | ROA | -154.34% | Short Interest | 0.79M | Perf YTD | -57.24% |
| Book/sh | 1.88 | P/C | 1.29 | EPS past 3/5Y | 67.06% 56.72% | ROE | -203.63% | 52W High | -77.36% ($13.43) | Perf Year | -73.24% |
| Cash/sh | 2.36 | P/FCF | - | Sales past 3/5Y | - | ROIC | -212.82% | 52W Low | 16.92% ($2.60) | Perf 3Y | -99.49% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 87.83% | Gross Margin | - | Volatility(W/M) | 7.95% 6.59% | Perf 5Y | -99.75% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.25 | Perf 10Y | -99.96% |
| Dividend Ex-Date | - | Quick Ratio | 2.76 | EPS Q/Q | 67.06% | Profit Margin | - | RSI (14) | 31.16 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.76 | Sales Q/Q | - | SMA20 | -16.32% ($3.63) | Beta | 1.22 | Target Price | $150 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/6/10 | SMA50 | -19.32% ($3.77) | Rel Volume | 0.5 | Prev Close | $3.31 |
| Employees | 31 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -20.28% ($3.81) | Avg Volume(3M) | 0.26M | Price | $3.04 |
| IPO | 2010/10/28 | Option/Short | No/Yes | Trades | 429 | Volume | 130,859 | Change | -8.16% |
🧬 BriaCell Therapeutics () is a clinical-stage biotech company headquartered in Vancouver, Canada, and Philadelphia, USA, developing **Bria-IMT™, a cell-based immunotherapy focused primarily on metastatic breast cancer**. The company is currently running a Phase 3 clinical trial in combination with a checkpoint inhibitor (CPI) and is also advancing its next-generation platform, Bria-OTS+, which targets both prostate cancer and breast cancer.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded less than usual. That is 50% of its average volume.
BCTX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 14.1%.
Tap to view numbers
It ranks #456 of 597 in the industry
Based on market cap of $26M.
ABVC#454 ABVC BioPharma Inc $27M PER - 
BYSI#455 BeyondSpring Inc $26M PER - BCTX#456 BriaCell Therapeutics Corp $26M PER - 
CELU#457 Celularity Inc $26M PER - 
PLRZ#458 Polyrizon Ltd $26M PER - 
FAQ
What kind of company is BCTX?
BCTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BCTX?
The market cap of BCTX is approximately $26M, ranking 5,120 within its sector.
What is the 52-week high and low for BCTX?
BCTX has recorded a 52-week high of $13.43 and a low of $2.60.
